# B. Paul Morgan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/b-paul-morgan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 39,924 |
| Field | Complement system in diseases |
| h-index | 104 |
| i10-index | 515 |
| Last Known Institution | UK Dementia Research Institute |
| OpenAlex ID | https://openalex.org/A5090102833 |
| ORCID iD | 0000-0003-4075-7676 |
| Works | 991 |

## Researcher papers

- [Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference](https://scholariq.org/papers/atypical-hemolytic-uremic-syndrome-and-c3-glomerulopathy-conclusions-from-a/)
- [C3 glomerulopathy: consensus report](https://scholariq.org/papers/c3-glomerulopathy-consensus-report/)
- [Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure](https://scholariq.org/papers/cardiac-myosin-activation-a-potential-therapeutic-approach-for-systolic-heart/)
- [Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.](https://scholariq.org/papers/human-protectin-cd59-an-18-000-20-000-mw-complement-lysis-restricting-factor/)
- [IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†](https://scholariq.org/papers/igg1-antibodies-to-acetylcholine-receptors-in-seronegative-myasthenia-gravis/)
- [Immunopathology of secondary‐progressive multiple sclerosis](https://scholariq.org/papers/immunopathology-of-secondary-progressive-multiple-sclerosis/)
- [Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome](https://scholariq.org/papers/gain-of-function-mutations-in-complement-factor-b-are-associated-with-atypical/)
- [Complement, a target for therapy in inflammatory and degenerative diseases](https://scholariq.org/papers/complement-a-target-for-therapy-in-inflammatory-and-degenerative-diseases/)
- [Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts](https://scholariq.org/papers/complement-mediated-lysis-by-anti-cd20-mab-correlates-with-segregation-into/)
- [Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects](https://scholariq.org/papers/complement-membrane-attack-on-nucleated-cells-resistance-recovery-and-non-lethal/)
- [Dimerization of complement factor H-related proteins modulates complement activation in vivo](https://scholariq.org/papers/dimerization-of-complement-factor-h-related-proteins-modulates-complement/)
- [Membrane proteins that protect against complement lysis](https://scholariq.org/papers/membrane-proteins-that-protect-against-complement-lysis/)

## Researcher topics

- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Neuroinflammation and Neurodegeneration Mechanisms](https://scholariq.org/topics/neuroinflammation-and-neurodegeneration-mechanisms/)
- [Erythrocyte Function and Pathophysiology](https://scholariq.org/topics/erythrocyte-function-and-pathophysiology/)
- [Blood groups and transfusion](https://scholariq.org/topics/blood-groups-and-transfusion/)

## Researcher university

- [UK Dementia Research Institute](https://scholariq.org/institutions/uk-dementia-research-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.